The goal of this study was to examine the therapeutic effects of a series (QC-47, QC-56, and OB-28) of potent,selective novel azole-based, competitive and reversible HO-1 inhibitors on the AD-associated behavioral and pathological deficits in APPswe/PS1ΔE9 mice. QC-47, QC-56, and OB-28 significantly attenuated oxidative damage in astrocytes transfected with the HMOX gene. OB-28 treatement was found to significantly counter behavioral deficits and neuropathological alterations in the transgenic mice. More specifically, OB-28 was found to attenuate oxidative damage, beta amyloid pathology and astrogliosis.
PK profile is reported in the Supplementary Material